First line therapy for metastatic renal cell carcinoma and gastrointestinal stromal tumors includes sunitinib which is a protein tyrosine kinase inhibitor targeting VEGF-R, c-kit, and PDGF-R. The gene discussed is PDGFRB; the disease is gastrointestinal stromal tumor.